Announcements
Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Takara, Clontech, and Cellartis brands. To keep you up to date with the latest happenings at Takara Bio USA, we have compiled our recent announcements and press releases below.
Takara Bio USA Holdings, Inc. completes acquisition of Rubicon Genomics, Inc.
Date: January 18, 2017
Categories: Press release
Mountain View, CA—January 18, 2017—Takara Bio USA Holdings, Inc. ("TBUSH") announced that it has completed the acquisition of Rubicon Genomics, Inc. ("Rubicon"). Rubicon has become a wholly-owned subsidiary of TBUSH as of January 17, 2017 (US local time). The Takara Bio Group provides a wide range of life science products and services under the Takara, Clontech, and Cellartis brands that assist discovery, translational and clinical scientists in the advancement of their work. The Rubicon acquisition will allow the Takara Bio Group to augment and expand its worldwide commercial offerings in next generation sequencing (NGS) sample preparation and expand into new markets.
Takara Bio USA Holdings and Rubicon Genomics announce merger agreement
Date: December 15, 2016
Categories: Press release
Mountain View, CA and Ann Arbor, MI—December 15, 2016—Takara Bio USA Holdings, Inc. ("TBUSH") and Rubicon Genomics, Inc. ("Rubicon"), today announced the signing of a merger agreement pursuant to which TBUSH will acquire Rubicon, a privately-owned company headquartered in Ann Arbor, Michigan. Rubicon is a leading provider of pre-analytical library preparation kits that increase the accuracy, efficiency and speed of genomic analysis.
Takara Bio USA, Inc. to supply single-cell RNA-seq kit for the Allen Cell Types Database
Date: November 1, 2016
Categories: Press release
Mountain View, CA—November 1, 2016—Takara Bio USA, Inc., (TBUSA; formerly Clontech Laboratories, Inc.) announced today that its SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing has been selected for the development of gene expression profiles of individual brain cells as part of the Allen Cell Types Database, a public resource available from the Allen Institute for Brain Science. This database will extend knowledge about the various cell types in the brain, which in turn may shed light on how the healthy brain functions and what goes wrong in diseases such as autism, Alzheimer's and Parkinson's.
Takara Bio announces the launch of human iPSC-derived beta cells for drug screening and diabetes research
Date: August 24, 2016
Categories: Press release
Mountain View, CA—August 24, 2016—Takara Bio USA, Inc., which specializes in human induced pluripotent stem cell (hiPSC)-derived cells and medias for scale-up and differentiation, has expanded its offering of tools for drug discovery and disease modeling. Takara Bio announced today the launch of fully differentiated, Cellartis hiPS beta cells for research use. These cells are well characterized and can provide physiologically relevant responses that are beneficial for modeling diabetes and beta-cell function, encouraging breakthroughs that advance research in personalized and regenerative medicine.
Takara Bio Europe expands its iPS cell culture medium product line for clinical scale-up and GMP production
Date: June 15, 2016
Categories: Press release
Göteborg, Sweden—June 15, 2016—Takara Bio Europe AB announced today that it is adding two xeno-free iPS cell culture media products, Cellartis DEF-CS 500 Xeno-Free GMP Grade Basal Medium and Cellartis DEF-CS 500 Xeno-Free 3D Spheroid Culture Medium. These products will be launched at the 2016 International Society for Stem Cell Research (ISSCR) Conference, June 22–25, in San Francisco, California, USA.
WaferGen Bio-systems and Takara Bio Inc. announce merger agreement
Date: May 13, 2016
Categories: Press release
Fremont, CA and Mountain View, CA—May 13, 2016—WaferGen Bio-systems, Inc. (NASDAQ: WGBS), a publicly held genomics technology company ("WaferGen"), and Takara Bio USA Holdings, Inc. ("TBUSH"), today announced that they have entered into a merger agreement pursuant to which TBUSH will acquire WaferGen. TBUSH is a wholly owned subsidiary of Takara Bio Inc. (TSE: 4974), a leading global biotechnology and life science company ("Takara Bio"). Takara Bio USA, Inc. ("TBUSA," formerly known as Clontech Laboratories, Inc.) is a wholly owned subsidiary of TBUSH and is a guarantor under the merger agreement.
Takara Bio USA and Integrated DNA Technologies announce collaboration to support targeted RNA sequencing
Date: April 26, 2016
Categories: Press release
Mountain View, CA—April 26, 2016—Takara Bio USA, Inc. (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., and Integrated DNA Technologies (IDT) today announced a new collaboration to support targeted RNA sequencing. This relationship will leverage IDT's unrivalled proficiency in the manufacture and quality control of long oligonucleotides and TBUSA's expertise in developing low-input solutions for next-generation sequencing (NGS) applications under the Clontech brand.
Clontech Laboratories, Inc. releases the SMART-Seq v4 Ultra Low Input RNA Kit for the Fluidigm C1 System
Date: April 16, 2016
Categories: Press release
Mountain View, CA—April 6, 2016—Clontech Laboratories, Inc., a wholly owned subsidiary of Takara Bio Inc., and Fluidigm Corporation today announced the recent launch of Clontech's SMART-Seq v4 Ultra Low Input RNA Kit for the Fluidigm C1 System. This kit, which is available for 4 and 10 IFCs (integrated fluidic circuits), allows high-quality cDNA synthesis starting from 96 single cells that have been isolated and processed with the Fluidigm C1 System, using a script available in the Fluidigm Script Hub.
Clontech Laboratories, Inc. releases TaKaRa Taq Hot Start Version GMP grade
Date: February 29, 2016
Categories: Press release
Mountain View, CA—February 29, 2016—Clontech Laboratories, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of TaKaRa Taq Hot Start Version GMP grade, which is manufactured by Takara Bio Inc. in a state-of-the-art, GMP-compliant facility located in Kusatsu City, Shiga Prefecture, Japan.
Clontech Laboratories, Inc. to release a highly sensitive kit for human T-cell receptor repertoire analysis
Date: January 20, 2016
Categories: Press release
Mountain View, CA—January 20, 2016—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the upcoming launch of the SMARTer Human TCR a/b Profiling Kit. This system leverages SMART technology and employs a 5' RACE-like approach to capture complete V(D)J variable regions of TCR transcripts, enabling users to analyze T-cell receptor (TCR) diversity from human RNA samples or directly from cells.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2023 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
